These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33492002)

  • 41. Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations.
    Zhang F; Chen L
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving AML Classification Using Splicing Signatures.
    Bowman TV
    Clin Cancer Res; 2020 Jul; 26(14):3503-3504. PubMed ID: 32317289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
    Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
    Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and biological implications of driver mutations in myelodysplastic syndromes.
    Papaemmanuil E; Gerstung M; Malcovati L; Tauro S; Gundem G; Van Loo P; Yoon CJ; Ellis P; Wedge DC; Pellagatti A; Shlien A; Groves MJ; Forbes SA; Raine K; Hinton J; Mudie LJ; McLaren S; Hardy C; Latimer C; Della Porta MG; O'Meara S; Ambaglio I; Galli A; Butler AP; Walldin G; Teague JW; Quek L; Sternberg A; Gambacorti-Passerini C; Cross NC; Green AR; Boultwood J; Vyas P; Hellstrom-Lindberg E; Bowen D; Cazzola M; Stratton MR; Campbell PJ;
    Blood; 2013 Nov; 122(22):3616-27; quiz 3699. PubMed ID: 24030381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The functional mechanisms of mutations in myelodysplastic syndrome.
    Nagata Y; Maciejewski JP
    Leukemia; 2019 Dec; 33(12):2779-2794. PubMed ID: 31673113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
    Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
    Tothova Z; Valton AL; Gorelov RA; Vallurupalli M; Krill-Burger JM; Holmes A; Landers CC; Haydu JE; Malolepsza E; Hartigan C; Donahue M; Popova KD; Koochaki S; Venev SV; Rivera J; Chen E; Lage K; Schenone M; D'Andrea AD; Carr SA; Morgan EA; Dekker J; Ebert BL
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Splicing factor mutations in myelodysplasia.
    Ogawa S
    Int J Hematol; 2012 Oct; 96(4):438-42. PubMed ID: 23054646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 56. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
    Moyo TK; Savona MR
    Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetics of MDS.
    Ogawa S
    Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
    Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Focal Adhesion Kinase as a Potential Target in AML and MDS.
    Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
    Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.